FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal
Executive Summary
GE Healthcare's gadolinium MRI imaging contrast agent Omniscan stands to lose following a safety review by a joint FDA advisory committee, while rival products with a proven safety advantage could gain from the expert panel's recommendations